[Skip to Content]
[Skip to Content Landing]
October 15, 2003

Cost-effectiveness of Treatment for Chronic Hepatitis C Infection—Reply

Author Affiliations

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2003;290(15):1994-1995. doi:10.1001/jama.290.15.1994-a

In Reply: In considering the impact of annual dollar caps on drug benefits for Medicare beneficiaries, we characterized 15 of the top 20 medications driving their drug expenditures as for the treatment of a "chronic" disease. This was to demonstrate that patients would likely require continuing medical treatment even after exhausting their yearly drug benefits. We took a conservative approach and included health conditions such as cardiovascular disease, hypercholesterolemia, and diabetes.